Choosing Variant Interpretation Tools for Clinical Applications: Context Matters

Other authors

Institut Català de la Salut

[Aguirre J, Padilla N, Özkan S, Riera C] Grup de Recerca en Bioinformàtica Clínica i Translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Feliubadaló L] Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [de la Cruz X] Grup de Recerca en Bioinformàtica Clínica i Translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-08-22T11:04:50Z

2023-08-22T11:04:50Z

2023-07-24



Abstract

Clinical variant interpretation; Healthcare costs; Pathogenicity prediction


Interpretación de variantes clínicas; Costes sanitarios; Predicción de patogenicidad


Interpretació de variants clíniques; Despeses sanitàries; Predicció de patogenicitat


Pathogenicity predictors are computational tools that classify genetic variants as benign or pathogenic; this is currently a major challenge in genomic medicine. With more than fifty such predictors available, selecting the most suitable tool for clinical applications like genetic screening, molecular diagnostics, and companion diagnostics has become increasingly challenging. To address this issue, we have developed a cost-based framework that naturally considers the various components of the problem. This framework encodes clinical scenarios using a minimal set of parameters and treats pathogenicity predictors as rejection classifiers, a common practice in clinical applications where low-confidence predictions are routinely rejected. We illustrate our approach in four examples where we compare different numbers of pathogenicity predictors for missense variants. Our results show that no single predictor is optimal for all clinical scenarios and that considering rejection yields a different perspective on classifiers.


This work was supported by research grants SAF2016-80255-R from the Spanish Ministerio de Economía y Competitividad (MINECO), PID2019-111217RB-I00 and TED2021-130342B-I00 from the Spanish Ministerio de Ciencia e Innovación, and by the European Regional Development Fund (ERDF) through the Interreg program POCTEFA (Pirepred, EFA086/15).

Document Type

Article


Published version

Language

English

Publisher

MDPI

Related items

International Journal of Molecular Sciences;24(14)

https://doi.org/10.3390/ijms241411872

info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-80255-R

info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-111217RB-I00

info:eu-repo/grantAgreement/ES/PEICTI2021-2023/TED2021-130342B-I00

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)